The effect of levetiracetam on rat bone mass, structure and metabolism

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10173388" target="_blank" >RIV/00179906:_____/13:10173388 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10173388

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0920121113002179" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0920121113002179</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.eplepsyres.2013.08.012" target="_blank" >10.1016/j.eplepsyres.2013.08.012</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effect of levetiracetam on rat bone mass, structure and metabolism

Popis výsledku v původním jazyce

Epilepsy is a condition affecting 0,5 - 1% of the population in developed countries. Antiepileptic drugs can adversely affect bone health. We report our findings in orchidectomised rats fed on levetiracetam-enriched diet for 12 weeks concerning the impact of levetiracetam (LEV) on bone markers, bone mineral density (BMD) and biomechanical properties. Compared to the control group we found lower fat mass, lower BMD in the area of the left femur, lower BMC (bone mineral content) in both femur a reduced OPG (osteoprotegerin), and an increased concentration CTX-I (corboxy-terminal cross-linking telopeptide of type I collagen) of borderline statistical significance. Our results suggest that in the ORX-rat model LEV may affect bone mass of the femoral diaphysis (cortical bone) and suggest that LEV may suppress bone turnover. We may assume that the reduction in serum OPG levels could be explained by the inhibition of osteoblast activity. But further studies in animals and humans will be neede

Název v anglickém jazyce

The effect of levetiracetam on rat bone mass, structure and metabolism

Popis výsledku anglicky

Epilepsy is a condition affecting 0,5 - 1% of the population in developed countries. Antiepileptic drugs can adversely affect bone health. We report our findings in orchidectomised rats fed on levetiracetam-enriched diet for 12 weeks concerning the impact of levetiracetam (LEV) on bone markers, bone mineral density (BMD) and biomechanical properties. Compared to the control group we found lower fat mass, lower BMD in the area of the left femur, lower BMC (bone mineral content) in both femur a reduced OPG (osteoprotegerin), and an increased concentration CTX-I (corboxy-terminal cross-linking telopeptide of type I collagen) of borderline statistical significance. Our results suggest that in the ORX-rat model LEV may affect bone mass of the femoral diaphysis (cortical bone) and suggest that LEV may suppress bone turnover. We may assume that the reduction in serum OPG levels could be explained by the inhibition of osteoblast activity. But further studies in animals and humans will be neede

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Epilepsy Research

ISSN

0920-1211

e-ISSN

—

Svazek periodika

107

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

56-60

Kód UT WoS článku

000328524800006

EID výsledku v databázi Scopus

—